We are pleased to announce that Kendall Killgore has been appointed Chief Science Officer.
In his role, Mr. Killgore leads global research and development (R&D) operations, driving the translation of high-pressure homogenization and high-shear processing procedures into clinical and manufacturing applications. With over 20 years of experience in nanoscale drug delivery systems, Mr. Killgore specializes in the scaling of high-shear processing and advancing innovative pipelines from initial discovery through Phase II clinical trials.
Prior to joining Dyhydromatics, Mr. Killgore served as the Director of Product Development at Kereos, Inc., where he spearheaded the preclinical development of oncology nanoparticle therapeutics. He holds Master’s degrees in Chemistry from Saint Louis University and Biology from Washington University in Saint Louis. He is also the Co-founder of Adeira Pharma, LLC, a St. Louis, Missouri, company developing targeted drug formulation technologies for next-generation therapeutics.